Diabetic nephropathy screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 9: Line 9:
* [[Screening]] for nephropathy in diabetes should begin at the time of diagnosis of [[type II diabetes mellitus]], since about 7% of patients may have damaged kidneys even in early stages of [[diabetes]].
* [[Screening]] for nephropathy in diabetes should begin at the time of diagnosis of [[type II diabetes mellitus]], since about 7% of patients may have damaged kidneys even in early stages of [[diabetes]].
* Minute levels of [[albumin]] ([[microalbuminuria]]) in the urine are not detectable with routine urine protein dipsticks.
* Minute levels of [[albumin]] ([[microalbuminuria]]) in the urine are not detectable with routine urine protein dipsticks.
* The incidence of diabetic nephropathy may particularly increase in patients with poor glycemic control, [[systemic hypertension]] and [[hyperlipidemia]].
* The incidence of diabetic nephropathy may particularly increase in patients with [[hyperglycemia|poor glycemic control]], [[systemic hypertension]] and [[hyperlipidemia]].
* If [[microalbuminuria]] is not present, the test must be repeated annually for both [[type I diabetes mellitus|type I]] and [[type II diabetes mellitus]] patients.
* If [[microalbuminuria]] is not present, the test must be repeated annually for both [[type I diabetes mellitus|type I]] and [[type II diabetes mellitus]] patients.
* There are two ways to screen patients for diabetic nephropathy:
** Spot urine sample test
** 24 hour and timed urine collection
* The spot urine sample collection is preferred as it is convenient to perform and has a high [[sensitivity]] as well as [[specificity]]. The 24 hour and timed urine collection method is cumbersome and is inaccurate because of improper urine collection techniques and timing.

Revision as of 21:16, 24 January 2013

Diabetic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic nephropathy screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy screening

CDC on Diabetic nephropathy screening

Diabetic nephropathy screening in the news

Blogs on Diabetic nephropathy screening

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Overview

Microalbumin levels in the urine is an excellent tool to look for early damage to kidneys secondary to diabetes. Albumin is a protein found normally in the serum, but it gets completely absorbed from the renal tubules when it is filtered into the nephron from the glomerulus. Hence, a damaged nephron will not reabsorb the albumin filtered by the glomerulus and it appears in the urine.

Screening

  • Screening for nephropathy in diabetes should begin at the time of diagnosis of type II diabetes mellitus, since about 7% of patients may have damaged kidneys even in early stages of diabetes.
  • Minute levels of albumin (microalbuminuria) in the urine are not detectable with routine urine protein dipsticks.
  • The incidence of diabetic nephropathy may particularly increase in patients with poor glycemic control, systemic hypertension and hyperlipidemia.
  • If microalbuminuria is not present, the test must be repeated annually for both type I and type II diabetes mellitus patients.
  • There are two ways to screen patients for diabetic nephropathy:
    • Spot urine sample test
    • 24 hour and timed urine collection
  • The spot urine sample collection is preferred as it is convenient to perform and has a high sensitivity as well as specificity. The 24 hour and timed urine collection method is cumbersome and is inaccurate because of improper urine collection techniques and timing.